ART: When to Start? – Case Discussion Roy M. Gulick, MD, MPH Professor of Medicine Chief, Division of Infectious Diseases Weill Medical College of Cornell.

Slides:

Advertisements

Similar presentations

9th Advanced HIV Course Aix-en-Provence 2011 Role of ARV as Prevention Martin Fisher Brighton and Sussex University Hospitals, UK.

Advertisements

Antiretroviral Therapy: An HIV Prevention Strategy? Wafaa El-Sadr, MD, MPH Columbia University Harlem Hospital New York.

PrEP has high efficacy for HIV-1 prevention among higher-risk HIV-1 serodiscordant couples: a subgroup analysis from the Partners PrEP Study Erin Kahle.

Perspectives on Outreach from the NYC Department of Health and Mental Hygiene Benjamin Tsoi, MD, MPH Bureau of HIV/AIDS Prevention and Control NYC Department.

HIV treatment as prevention Stephen Kegg. 2 Learning Outcomes Overview of HIV management HIV transmission risks Current prevention strategies Which new.

Monica Gandhi MD, MPH Associate Professor and Women’s HIV Clinic provider, HIV/AIDS Division San Francisco General Hospital/ UCSF Safe Poz Love, U.S. Positive.

HIV in the United Kingdom: 2013 HIV and AIDS Reporting Section Centre for Infectious Disease Surveillance and Control (CIDSC) Public Health England London,

Treatment of HIV Stops Transmission : Where DO We Go From Here? Cohen et al Lancet, Nov Myron S. Cohen, MD Yergan-Bate Professor Medicine, Microbiology.

Maurice Cook ( EM Designs Group, Inc.) The End of AIDS Transmission? Robert M Grant, June 2012.

HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.

Does Africa need a rectal microbicide? IRMA and AVAC presentation 27 September 2011 Salim S. Abdool Karim Pro Vice-Chancellor (Research), University of.

HIV Prevention Biomedical A New Landmark in the Field of HIV Treatment

TasP is not enough Stipulated that TasP is effective in reducing infectiousness of the treated person – But much more is required. TasP requires effective.

HIV Prophylaxis: Following Occupational and Non-Occupational Exposure Nanik (Nayri) Hatsakorzian Pharm.D./MPH candidate 2014 Touro University, College.

INA-RESPOND Test and Treat Study

1 The START Trial: On the Shoulders of SMART 5 years after SMART INSIGHT Satellite Session WAC, Washington DC, July 2012.

P REPARING FOR P RE P: FROM THEORY TO PRACTICE K EY POPULATIONS Dr Oscar Radebe.

Epidemiology of HIV and Access to Prevention services, Tanzania Joint Biennial HIV National Response Review Stakeholders meeting. November, 2014 Blue Pearl.

HIV Science Update: From Rome to Addis – Biomedical Prevention Elly T Katabira, FRCP Department of Medicine Makerere University College of Health Sciences.

Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.

Use of Antivirals in Prevention Oral and Topical Prophylaxis

The potential and challenges of ARV-based HIV prevention: An overview

A Webinar Hosted by The National Harm Reduction Coalition The National Black Leadership Commission on AIDS The Coalition for Positive Health Empowerment.

ART Regimen Selection and Treatment Initiation for PMTCT Programs Lara Stabinski, MD, MPH Medical Officer Clinical Services S/GAC June 18, 2012.

Characteristics and Oral PrEP Adherence in the TDF2 Open-Label Extension in Botswana Henderson FL 1, Taylor AW 1, Chirwa LI 2,Williams TS 1,3, Borkowf.

Slide 1 of 9 From J Marrazzo, MD, at Los Angeles, CA: April 22, 2013, IAS-USA. IAS–USA Jeanne Marrazzo, MD, MPH Professor of Medicine University of Washington.

START study: UK-CAB July2015 Community feedback: START study Simon Collins HIV i-Base

Cindra Feuer and Marc-André LeBlanc HRCF, 21 April 2010 ARV-based Prevention.

IAS–USA When to Start Antiretroviral Therapy Constance A. Benson, MD Professor of Medicine University of California San Diego FINAL: Presented.

Slide #1 Antiretroviral Management in 2012 Discussion of the IAS-USA Updated HIV Treatment Guidelines JAMA, July The International Antiviral Society–

The Strategic Use of ARVs | IAC Satellite, July 22, |1 | Strategic Use of Antiretroviral Drugs WHO Perspective for Future Guidelines Chair of WHO.

………………..…………………………………………………………………………………………………………………………………….. Pre-Exposure Prophylaxis: The Time is Now Carlos Malvestutto, MD, MPH Medical Director FACES.

Case 1: 23-year-old Male Student Clinical Director, Division of Infectious Diseases Brigham and Women’s Hospital Professor of Medicine Harvard Medical.

HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System HIV in the United Kingdom: 2012 Overview.

Looking back, looking forward: what we know and don’t know about oral PrEP and tenofovir gel for preventing HIV in women Jared Baeten MD PhD Departments.

Looking back, looking forward: what we know and don’t know about oral PrEP and tenofovir gel for preventing HIV in women Jared Baeten MD PhD Departments.

A PEP and PrEP Update Jeffrey D. Klausner, MD, MPH Black AIDS Institute-UCLA African-American University September 2014 Special thanks to Raphael Landovitz,

What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate? Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID,

TREATMENT OF SERO-DISCORDANT COUPLES: IMPLICATIONS FOR YOUNG PEOPLE JJ KUMWENDA (FRCP-UK)

HIV-infected subjects with CD4 350 to 550 cells/mm serodiscordant couples HPTN 052 Study Design Immediate ART CD Delayed ART CD4

Michael Hughes, MD Assistant Clinical Professor UCR Eisenhower Medical Associates.

Prevention trials pipeline MOSY3. Willard Cates, HIV Prevention Research: The Optimist’s.

Pharmacist-Managed HIV Pre-Exposure Prophylaxis (PrEP) Clinic: Preliminary Outcomes From an Urban Community Health Clinic Mark T. Sawkin, PharmD, AAHIVP.

IAS July 1 The Caprisa 004 result in context Sheena McCormack Clinical Scientist MRC Clinical Trials Unit.

Jeanne M. Marrazzo, MD, MPH Professor of Medicine University of Washington Seattle, Washington A Shot in the Arm for HIV Prevention? Opportunities and.

Microbicides and PrEP: Back to Basics Wednesday July 25, 2012 ADM Kashuba.

Case 4: 65-year-old Man Newly Diagnosed, Has Other Health Issues Paul E. Sax, MD Clinical Director, Division of Infectious Diseases Brigham and Women’s.

PrEP Update: The science, new tools, and next steps Dawn K. Smith MD, MS, MPH Division of HIV/AIDS Prevention, CDC “The findings and conclusions in this.

N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Pre-exposure Prophylaxis for HIV Prevention Efficacy and the importance of adherence Joanne Stekler,

Universal Opt-Out Screening for HIV in Health Care Settings, Cost Effectiveness in Action Douglas K. Owens, MD, MS VA Palo Alto Health Care System and.

Dr. William P. Howlett Matthew P. Rubach, MD Dr. Neema W. Minja Department of Internal Medicine, KCMC KCMC/Duke Collaboration HIV in Tanzania: Current.

HIV and Women Collaborating Across Borders to Advance the Health of Women IAS 2012 Gina M. Brown, M.D. July 22, 2012.

Henry Masur, MD Bethesda, Maryland

Pre-exposure Prophylaxis (PrEP) for HIV Prevention: What’s the Future? Joanne Stekler, MD MPH Assistant Professor of Medicine University of Washington.

Session: Treatment is Prevention? 16 th International Conference on AIDS and Sexually Transmitted Infections in Africa, Addis Ababa, Ethiopia Catherine.

PRE-EXPOSURE PROPHYLAXIS in Pregnancy in South Africa

PrEP for HIV Prevention

Module 4 (e) Pregnancy and Breast Feeding

Module 4 (c) Stopping PrEP

Pharmacokinetics: HIV Drugs

PrEP: A Case-by-Case Approach

HIV and the ART of Prevention

Pre-Exposure Prophylaxis (PrEP) for HIV Infection

Module 1: INTRODUCTION TO ORAL PrEP Version: August 2018.

Module 1: INTRODUCTION TO ORAL PrEP Version: December 2018.

100 Partners PrEP[5] Efficacy 75% Adherence 81% 80

Module 1: INTRODUCTION TO ORAL PrEP Version: August 2018.

Lesson 3: Treatment as Prevention

Module 1: INTRODUCTION TO ORAL PrEP Version: June 2019.

HIV Preexposure Prophylaxis (PrEP) 2019

Presentation transcript:

ART: When to Start? – Case Discussion Roy M. Gulick, MD, MPH Professor of Medicine Chief, Division of Infectious Diseases Weill Medical College of Cornell University New York City, USA

Case: NR NR is a 32 year old accountant referred to to discuss HIV treatment options. Past History: –gonorrhea 1 year ago that responded to rx –tested HIV negative “every year since 2000” Meds: none Social History: Sexually active gay man, not currently in a committed relationship; has health insurance through work.

Case: NR (continued) Physical Exam: normal Labs: –CBC, chemistries, liver function tests normal –HIV antibody + –HIV RNA 47,000 –CD4 count 635/µL He understands the requirements of ART and is willing to start if you recommend it.

Question Asymptomatic, VL 47,000; CD4 635 Do you recommend ART now? 1.Yes 2.No 3.It depends

When to Start? AIDS/ symptoms CD4 <200 CD CD4 > CD4 >500 US DHHS YES IAS-USA 2012 JAMA 2012;308:387 YES UK 2012 HIV Med 2012; YES certain patients EACS alsociety.org/ YES certain patients WHO adult2010/en YES NO 3 YES

ART for “Certain Patients” with CD4 >350 BHIVA Guidelines 2012: AIDS (e.g., KS) HIVAN ITP Neurocognitive HBV HCV (CD4 <500) Non-AIDS malignancies requiring rx EACS Guidelines 2012: AIDS, including TB HIVAN Neurocognitive HBV HCV (CD4 <500) Hodgkin’s lymphoma HPV-associated cancer

Case NR (continued) He says he’ll think about it and schedules an appointment for additional labs and a follow-up visit in 3 months. At the 3 month visit: –Asymptomatic with normal physical exam –Hepatitis B surface Ag -, Ab +; Hep C Ab - –HIV RNA 53,000; CD4 642 Met a new partner 2 months ago who is “the love of his life” and is HIV-negative. He knows “all about” safe sex but also wants to do “everything he can” to protect his partner.

Question Asymptomatic, VL 53,000; CD4 642; HIV-negative partner Do you recommend ART now? 1.Yes 2.No 3.Maybe

HPTN 052 1,763 discordant couples (97% heterosexual) in Africa, Asia, Americas with HIV+ with CD HIV+ partner randomized to start cART immediately or deferred until CD4 <250 DSMB Interim analysis: 90% on ART had HIV RNA < incident cases of HIV 29 linked genetically to partner 96% reduction in transmission! Cohen #MOAX0102 and NEJM 2011;365:493 years probability New HIV infections (all) 28 cases 1 case

ART + Serodiscordant Couples BHIVA Guidelines 2012: “…if a patient with a CD4 >350 wishes to start ART to reduce the risk of transmission to partners, this decision is respected and ART is started.” EACS Guidelines 2012: “…should be strongly considered and actively discussed.”

Case NR (continued) He agrees to start ART. He also understands he should continue to practice safe sex with his partner. At his routine visit 3 months later, he has not missed an ART dose and is VL is 2,350. He says he’s heard something about giving HIV- uninfected people HIV drugs to protect them and asks what you would recommend for his partner?

Question HIV+ MSM on ART At 3 months, VL ↓ 2,350 cps/ml HIV- partner Do you recommend PrEP? 1.Yes 2.No 3.Maybe

Question HIV+ MSM on ART At 6 months, VL <20 cps/ml HIV- partner Do you recommend PrEP? 1.Yes 2.No 3.Maybe

Oral PrEP Studies Study (reference)f Study population Design Results: Reduction in HIV Infection IPREX Grant NEJM 2010;363: gay menTDF/FTC vs. placebo TDF/FTC: 45% (92% if TFV detected) CDC – TDF-2 Thigpen NEJM 2012;367: Botswana adults (45% women) TDF/FTC vs. placebo TDF/FTC: 63% (84% if TFV detected) Partners PREP Baeten NEJM 2012;367: discordant African couples TDF vs. TDF/FTC vs. placebo TDF: 67% TDF/FTC: 75% (86-90% if TFV detected)

Oral PrEP Studies Study (reference) Study population Design Results: Reduction in HIV Infection FEM-PREP Van Damme NEJM 2012;367: women in Kenya, South Africa, Tanzania TDF/FTC vs. placebo TDF/FTC: 6% (adherence < 40%) VOICE Marrazzo CROI 2013 #26LB 5029 women in South Africa, Uganda, Zimbabwe 1% TDF gel vs. placebo gel; oral TDF vs. TDF/FTC vs. placebo No study drugs effective (adherence < 30%)

DeCock and El-Sadr NEJM 2013;368:886 When to start ART? 2013

Acknowledgments Cornell HIV Clinical Trials Unit (CCTU) Division of Infectious Diseases Weill Medical College of Cornell University AIDS Clinical Trials Group (ACTG) Division of AIDS, NIAID, NIH The patient volunteers!